Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

ClinicalTrials.gov ID: NCT01359150

Public ClinicalTrials.gov record NCT01359150. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double Blind, Placebo Controlled Phase 2 Study To Assess The Immune Response Following Administration Of Influenza And Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving Cp-690,550 Or Placebo Cp-690,550 With And Without Background Methotrexate

Study identification

NCT ID
NCT01359150
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
223 participants

Conditions and interventions

Interventions

  • CP-690,550 Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2011
Primary completion
Jan 31, 2012
Completion
Jan 31, 2012
Last update posted
Mar 28, 2013

2011 – 2012

United States locations

U.S. sites
51
U.S. states
26
U.S. cities
48
Facility City State ZIP Site status
Pfizer Investigational Site Gilbert Arizona 85234
Pfizer Investigational Site Paradise Valley Arizona 85253
Pfizer Investigational Site Jonesboro Arkansas 72401
Pfizer Investigational Site Fair Oaks California 95628
Pfizer Investigational Site Los Angeles California 90095
Pfizer Investigational Site Roseville California 95661
Pfizer Investigational Site Upland California 91786
Pfizer Investigational Site Boulder Colorado 80304
Pfizer Investigational Site Trumbull Connecticut 06611
Pfizer Investigational Site Jacksonville Florida 32216
Pfizer Investigational Site Naples Florida 34102
Pfizer Investigational Site New Port Richey Florida 34652
Pfizer Investigational Site Port Richey Florida 34668
Pfizer Investigational Site Tampa Florida 33613
Pfizer Investigational Site Zephyrhills Florida 33542
Pfizer Investigational Site Morton Grove Illinois 60053
Pfizer Investigational Site Rockford Illinois 61107
Pfizer Investigational Site Vernon Hills Illinois 60061
Pfizer Investigational Site Wichita Kansas 67208
Pfizer Investigational Site Lexington Kentucky 40504
Pfizer Investigational Site Cumberland Maryland 21502
Pfizer Investigational Site Leominster Massachusetts 01453
Pfizer Investigational Site Worcester Massachusetts 01605
Pfizer Investigational Site Worcester Massachusetts 01608
Pfizer Investigational Site Bingham Farms Michigan 48025
Pfizer Investigational Site Edina Minnesota 55435
Pfizer Investigational Site Columbia Missouri 65203
Pfizer Investigational Site Columbia Missouri 65212
Pfizer Investigational Site Lebanon New Hampshire 03756
Pfizer Investigational Site Albany New York 12206
Pfizer Investigational Site Binghamton New York 13905
Pfizer Investigational Site Olean New York 14760
Pfizer Investigational Site Rochester New York 14618
Pfizer Investigational Site Charlotte North Carolina 28210
Pfizer Investigational Site Rocky Mount North Carolina 27804
Pfizer Investigational Site Minot North Dakota 58701
Pfizer Investigational Site Dayton Ohio 45417
Pfizer Investigational Site Oklahoma City Oklahoma 73112
Pfizer Investigational Site Bethlehem Pennsylvania 18015
Pfizer Investigational Site Duncansville Pennsylvania 16635
Pfizer Investigational Site Wyomissing Pennsylvania 19610
Pfizer Investigational Site Greenville South Carolina 29601
Pfizer Investigational Site Knoxville Tennessee 37909
Pfizer Investigational Site Austin Texas 78705
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site Mesquite Texas 75150
Pfizer Investigational Site Seattle Washington 98104
Pfizer Investigational Site Seattle Washington 98122
Pfizer Investigational Site Tacoma Washington 98405
Pfizer Investigational Site Vancouver Washington 98664
Pfizer Investigational Site Clarksburg West Virginia 26301

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01359150, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 28, 2013 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01359150 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →